Newsroom
Strive to Deliver Breakthroughs
-
May 25, 2022
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 25, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successfully ...
View more -
May 10, 2022
Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting
Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 10, 2022 Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical...
View more -
May 06, 2022
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board
Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 6, 2022 Harbour BioMed (“HBM”, HKEX:02142), a global biopharmaceutical company co...
View more -
April 14, 2022
Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer
CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - April 14, 2022 Harbour BioMed (“HBM” or the “Company”; HKEX: 021...
View more -
April 07, 2022
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
Cambridge, MA, Rotterdam, NL, Suzhou, CN— April 7, 2022 Harbour BioMed (“HBM”, “the Company”, HKEX: 02142), a globa...
View more -
April 06, 2022
Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Cambridge, MA, Rotterdam, NL, Suzhou, CN— April 6, 2022 Harbour BioMed (“HBM”, HKEX: 02142), a global biopharmaceutical company ...
View more -
March 25, 2022
Harbour BioMed Reports Full Year 2021 Financial Results: Two Late-stage Programs Are Accelerating Towards Commercialization with Robust Innovation and Globalization Capabilities
CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - March 25, 2022 Harbour BioMed (“HBM” or the “Company”; HKEX: 021...
View more -
February 28, 2022
Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia
Cambridge, MA, Rotterdam, NL, Suzhou, CN— February 28, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has been appr...
View more -
February 21, 2022
Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody in Asthma
Cambridge, MA, Rotterdam, NL, Suzhou, CN - February 21, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that China National Me...
View more -
January 24, 2022
Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 24, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successful...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1